SynthesisJournal of cancer research and clinical oncology2011
Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a meta-analysis.
Synthesis in Journal of cancer research and clinical oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 4 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Prognostic Biomarkers for Gastric Cancer: An Umbrella Review of the Evidence.Frontiers in oncology · 2019Pooled it
- Can vascular endothelial growth factor and microvessel density be used as prognostic biomarkers for colorectal cancer? A systematic review and meta-analysis.TheScientificWorldJournal · 2014Pooled it
- Clinical and prognostic significance of HIF-1α, PTEN, CD44v6, and survivin for gastric cancer: a meta-analysis.PloS one · 2014Pooled it
- Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer.BMC cancer · 2013Pooled it
- A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with AvastinBritish journal of clinical pharmacology · 2018Trial
- Trial
- Article
- The Expression and Prognostic Significance of VEGF and CXCR4 in Gastric Cancer: Correlation with Angiogenesis, Lymphangiogenesis and Progression.Current issues in molecular biology · 2022Article
- VEGF as a potential molecular target in periodontitis: a meta-analysis and microarray data validation.Journal of inflammation (London, England) · 2021Article
- Association betweenOpen access Macedonian journal of medical sciences · 2018Article
- Optimal management of resected gastric cancer.Cancer management and research · 2018Review
- Effect of ERβ-regulated ERK1/2 signaling on biological behaviors of prostate cancer cells.American journal of translational research · 2017Article
- The Different Effect of VEGF Polymorphisms on the Prognosis of Non-Small Cell Lung Cancer according to Tumor Histology.Journal of Korean medical science · 2016Article
- Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference.Cancer letters · 2016Review
- Linifanib (ABT-869) Potentiates the Efficacy of Chemotherapeutic Agents through the Suppression of Receptor Tyrosine Kinase-Mediated AKT/mTOR Signaling Pathways in Gastric Cancer.Scientific reports · 2016Article
- Emerging molecular basis of hematogenous metastasis in gastric cancer.World journal of gastroenterology · 2016Review
- Prognostic and clinical significance of STAT3 and MMP9 in patients with gastric cancer: a meta-analysis of a Chinese cohort.International journal of clinical and experimental medicine · 2015Article
- The siRNA cocktail targeting VEGF and HER2 inhibition on the proliferation and induced apoptosis of gastric cancer cell.Molecular and cellular biochemistry · 2014Article
- AEG-1 promotes anoikis resistance and orientation chemotaxis in hepatocellular carcinoma cells.PloS one · 2014Article
- Genetic mutation analysis of human gastric adenocarcinomas using ion torrent sequencing platform.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study was to comprehensively and quantitatively summarize available evidences for the use of VEGF protein to evaluate the clinicopathological and prognostic role of VEGF expression in Asian patients with gastric cancer.
methodSearches were applied to MEDLINE, EMBASE, and the Cochrane Library databases until June 2010, without language restrictions. A meta-analysis was performed to clarify the impact of VEGF expression on clinicopathological parameters or over survival (OS) in gastric cancer.
resultsOur combined results showed that VEGF expression in Asian patients with gastric cancer was significantly higher in the case-control studies (1,194 patients and 1,618 controls) (odds ratio [OR] = 112.41, 95% confidence interval [CI] = 64.12-197.06). All the analyses estimated favored a stronger link between the high VEGF expression and the poor 5-year overall survival (1,236 patients) (risk ratio [RR] = 2.45, 95% CI = 2.11-2.83, P = 0.000). When stratifying the studies by the pathological variables, the depth of invasion (3,094 patients) (OR = 1.95, 95% CI = 1.40-2.71, P = 0.000), lymph node metastasis (3,240 patients) (OR = 1.82, 95% CI = 1.29-2.57, P = 0.001), distant metastasis (1,980 patients) (OR = 2.76, 95% CI = 1.22-6.25, P = 0.015), vascular invasion (1,803 patients) (OR = 2.61, 95% CI = 2.09-3.27, P = 0.000), and TNM stage (1,819 patients) (OR = 1.92, 95% CI = 1.57-2.36, P = 0.000) provided significant prognostic information.
conclusionOur results indicate that VEGF can potently predict the overall survival in Asian patients with gastric cancer. Importantly, VEGF may be converted from candidate to the routine clinical setting for clinicians to predict the outcome of single patient with gastric carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.